↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Cevian's **14%** Smith & Nephew stake now exceeds **$2.1 billion**, largest medical-device position for the activist during a CEO search at decade-low valuations.
14%
in Smith &
$14.6 billion
London-listed medical device manufacturer
11.2x
forward earnings
34%
discount to peers Stryker and Zimmer Biomet
Cevian Capital filed a Schedule 13D amendment in late July disclosing a stake above 14% in Smith & Nephew, the $14.6 billion London-listed medical device manufacturer. The Swedish activist has now accumulated shares for five consecutive quarters, building what is likely its largest single position outside European industrial conglomerates. Smith & Nephew trades at 11.2x forward earnings, a 34% discount to peers Stryker and Zimmer Biomet, despite comparable operating margins in the 18-19% range.
The timing matters. Smith & Nephew announced CEO Deepak Nath's departure in May after eighteen months in the role, naming CFO Anne-Françoise Nesmes as interim chief while the board conducts a search expected to conclude by year-end. The company has missed analyst estimates in four of the past six quarters, with its orthopaedics division growing at 3.1% versus the sector's 5.8% average. Cevian's stake crossed 10% in Q1 2024, then 12% in Q4 2023 filings, each time without board representation or public campaign materials. The latest amendment suggests accumulation continued through June and early July, prior to the CEO transition announcement reaching the market.
Cevian runs $15 billion and specializes in operational overhauls at underperforming European industrials, typically holding 5-10 concentrated positions for three to seven years. Portfolio companies include ThyssenKrupp, where Cevian pushed for steel-division separation, and Pandora, where margins expanded 680 basis points over a four-year engagement. Smith & Nephew's 23% share-price decline since January 2022 reflects concerns over U.S. market-share losses in knee implants and delayed product launches in the advanced wound-care segment, which accounts for 29% of revenue. The company's return on invested capital has fallen from 12.4% in 2019 to 8.9% in the trailing twelve months, below its 10.2% weighted average cost of capital.
Allocators should watch for three catalysts. First, the CEO appointment, expected between October and December, will signal whether the board accepts operational restructuring or opts for continuity. Second, Smith & Nephew's Q3 earnings in late October will show whether the orthopaedics division stabilized after two quarters of sequential deceleration. Third, any Cevian board-seat request would appear in a subsequent 13D amendment, historically filed 60-90 days after the activist crosses 12% in European cross-listings. The firm has not yet issued a public letter or white paper.
Smith & Nephew's enterprise value sits at $16.8 billion with $2.3 billion in net debt, offering a break-up scenario where the sports medicine and advanced wound-care units could trade separately at sector multiples in the 14-16x range. Cevian's average holding period and the CEO search timeline place the next inflection point in Q4 2024.
Branded by POPS4 · proof in 60 seconds
For the principal
CEO search concluding Q4 offers natural governance-review window; orthopaedics restructuring could unlock $3-4 billion in separate-unit valuation within eighteen months.
For the operator
Watch October earnings for orthopaedics stabilization and any 13D amendment signaling board-seat request; break-up scenario prices in at $18-21 per ADR versus current $13.40.
For the house
Huang Goodman holds 0.8% passive Smith & Nephew position in European Healthcare sleeve; consider 1.2-1.5% active weight if Cevian formalizes board engagement by November.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.